Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

The European Union Policy in the Field of Rare Diseases

Montserrat Moliner A. · Waligóra J.

Author affiliations

Directorate of Public Health, European Commission, Luxembourg, Luxembourg

Related Articles for ""

Public Health Genomics 2013;16:268-277

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: February 03, 2014
Issue release date: February 2014

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG

Abstract

Background: Rare diseases (RDs), including those of genetic origin, are defined by the European Union (EU) as life-threatening or chronically debilitating diseases, which are of low prevalence (fewer than 5 per 10,000). The specificities of RDs - a limited number of patients and scarcity of relevant knowledge and expertise - single them out as a unique domain of a very high European added value. Methods: Legal instruments at the disposal of the EU, in terms of Article 152 of the Treaties, are very limited. However, a combination of instruments using the research and the pharmaceutical legal regulations, an intensive and creative use of funding from the Second Health Programme, the adoption of the Commission Communication in November 2008, the Council Recommendation in June 2009, and the Directive on cross-border healthcare in 2011 have permitted the creation of a solid basis that Member States have considered as sufficient to place RDs in a privileged position in the health agenda. Results: As a result, an operational framework to act in the field of RDs with European coordination in several areas would be possible (orphan medicinal products, national plans on rare diseases, ICD-10 revision, European Reference Networks, European Platform for Rare Diseases registration, IRDiRC, European Committee of Experts, etc.). Conclusion: RDs is a field with an enormous potential for European cooperation.

© 2013 S. Karger AG, Basel


References

  1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=en&numdoc=32000R0141&model= guichett.
  2. Decision No 1295/1999/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003). http://eur-lex.europa.eu/pri/en/oj/dat/1999/l_155/l_15519990622en00010005.pdf.
  3. Communication COM(2008) 679 final from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges. http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf.
  4. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF.
  5. Annual report of the European Medicines Agency 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2013/04/WC500142077.pdf.
  6. EUCERD Recommendation on CAVOMP (Clinical Added Value for Orphan Medicinal Products) Information Flow. http://www.eucerd.eu/?post_type=document&p=1446.
  7. Process of Corporate Responsibility in the field of Pharmaceuticals - DG ENTR European Commision. http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/process_on_corporate_responsibility/index_en.htm.
  8. Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP) - Final Report - DG ENTR European Commision. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/orphans_report_en.pdf.
  9. Web site of the European Commission on the Seventh Framework Programme (2007-2013). http://ec.europa.eu/research/fp7/.
  10. ERA NET Research Programme on Rare Diseases. http://www.e-rare.eu/.
  11. Centres of Reference for rare diseases in Europe: State-of-the-art in 2006 and recommendations of the Rare Diseases Task Force. A technical and scientific report from an expert group of the European Union Rare Diseases Task Force. http://ec.europa.eu/health/ph_threats/non_com/docs/contribution_policy.pdf.
  12. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF.
  13. EUCERD Recommendation on Quality Criteria for Centres of Expertise for Rare Diseases in Member States. http://ec.europa.eu/health/rare_diseases/docs/eucerd_recommendation_2011_en.pdf.
  14. EUCERD Recommendation to the European Commission and the Member States on European Reference Networks for Rare Diseases. http://www.eucerd.eu/?post_type= document&p=2207.
  15. Orphanet. The portal on rare diseases and orphan drugs, a project supported by the European Union. http://www.orpha.net/.
  16. World Health Organization: web site on the International Classification of Diseases. http://www.who.int/classifications/icd/en/index.html.
  17. EUCERD: Workshop on cross-referencing of terminologies, 27-28 September 2012, Paris - organised through the EUCERD Joint Action No 2011 22 01 and Eurogentest 2. http://www.eucerd.eu/?page_id=1799.
  18. Orphanet Report Series: Diseases Registries in Europe. http://www.orpha.net/orphacom/ cahiers/docs/GB/Registries.pdf.
  19. EPIRARE: European Platform for Rare Diseases Registries. http://www.epirare.eu/.
  20. European Commission: Supporting rare diseases registries and providing a European Platform for rare diseases registration. http://ec.europa.eu/health/rare_diseases/policy/registries/index_en.htm.
  21. RD-Connect: An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. http://rd-connect.eu/.
  22. PARENT: Cross-border Patients Registries Initiative: Joint Action. http://www.patientregistries.eu/Stranky/Home.aspx.
  23. EUCERD Joint Action. http://www.eucerd.eu/?page_id=54.
  24. European Surveillance of Congenital Anomalies (EUROCAT). http://www.eurocat-network.eu.
  25. SCPE: Surveillance of Cerebral Palsy in Europe. http://www.scpenetwork.eu/.
  26. ERIC: European Research Infrastructure Consortium. http://ec.europa.eu/research/infrastructures/index_en.cfm?pg=eric.
  27. EUROPLAN: The European Project for Rare Diseases National Plans Development. http://www.europlanproject.eu/.
  28. EUCERD Recommendations on Core Indicators for Rare Disease National Plans/Strategies. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_Indicators_adopted.pdf.
  29. EURORDIS: European Organisation for Rare Diseases. http://www.eurordis.org.
  30. IRDiRC: International Rare Disease Research Consortium. http://www.irdirc.org/.
  31. EUCERD: European Union Committee of Experts on Rare Diseases. http://www.eucerd.eu/.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: February 03, 2014
Issue release date: February 2014

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.